

PTO/SB/08 Equivalent

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Multiple sheets used when necessary) SHEET 1 OF 1	Application No.	08/793,653
	Filing Date	February 27, 1997
	First Named Inventor	De Sauvage
	Art Unit	1646
	Examiner	Zachary C. Howard
	Attorney Docket No.	GENENT.052CP2

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear


FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
ZM ↓ ✓	1	CAMPFIELD et al. Strategies and Potential Molecular Targets for Obesity Treatment. Science 280: 1383-1387. 29 May 1998	
	2	HIRSCH, J. The search for new ways to treat obesity. PNAS, 99(14): 9096-9097. 9 July 2002	
	3	RUDIHOFF et al. Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci USA, 79: 1979-1983, March 1992	
	4	WOODS et al. Signals That Regulate Food Intake and Energy Homeostasis. Science 280: 1378-1383. 29 May 1998	

1988819
101205



Examiner Signature	<i>Zach Howard</i>	Date Considered	1/27/06
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

T¹ - Place a check mark in this area when an English language Translation is attached.


INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Multiple sheets used when necessary) 	Application No.	08/793,653	
	Filing Date	February 27, 1997	
	First Named Inventor	Frederic De Sauvage	
	Art Unit	1646	
	Examiner	Zachary C. Howard	
SHEET 1 OF 1		Attorney Docket No.	GENENT.052CP2

U.S. PATENT DOCUMENTS				
Examiner Initials	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
 	1	BREWERTON et al. "Reduced plasma leptin concentrations in bulimia nervosa," Psychoneuroendocrinology, 2000, 25:649-658	
	2	CAMPFIELD et al. "Strategies and Potential Molecular Targets for Obesity Treatment", Science, May 1998, 280:1383-1387	
	3	CHEN et al. "Evidence That the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in db/db Mice," Cell, Feb 1996, 84:491-495	
	4	COLEMAN, D.L. "Obese and Diabetes: Two Mutant Genes Causing Diabetes-Obesity Syndromes in Mice," Diabetologia, 1978, 14:141-148	
	5	FAROOQI et al. "Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency," New England J Med, Sept 1999, 341(12):879-884	
	6	HANAKI et al. "Leptin Before and After Insulin Therapy in Children with New-Onset Type 1 Diabetes," J Clin Endo & Metab, 1999, 84(5):1524-1526	
	7	HEYMSFIELD et al. "Recombinant Leptin for Weight Loss in Obese and Lean Adults," JAMA, Oct 1999, 282(16):1568-1575	
	8	HUKSHORN et al. "Weekly Subcutaneous Pegylated Recombinant Native Human Leptin (PEG-OB) Administration in Obese Men," J Clin Endo & Metab, 2000, 85(11):4003-4008	
	9	JIMERSON et al. "Decreased Serum Leptin in Bulimia Nervosa", J Clin Endo & Metab, 2000, 85(12):4511-4514	
	10	REDDY et al. "Immunohistochemical demonstration of leptin in pancreatic islets of non-obese diabetic and CD-1 mice: Co-localization in glucagon cells and its attenuation at the onset of diabetes," J Mol Histology, 2004, 35:511-519	
	11	ROSENBAUM et al. "Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones," J Clin Endo & Metab, May 2002, 87(5):2391-2394	
	12	TAYLOR et al. "Impact of Binge Eating on Metabolic and Leptin Dynamics in Normal Young Women," J Clin Endo & Metab, 1999, 84(2):428-434	

2083452/112205

Examiner Signature		Date Considered	1/27/06
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

T¹ - Place a check mark in this area when an English language Translation is attached.